Vorasidenib
servier
['specta', 'sarcoma', 'indigo']
idh 1/2 mutation finally validated as actionable, clinically relevant target in low-grade glioma with the spectacular results from the indigo trial shown at asco. next in line waiting for a practice-changing idh inhibitor trial: chondrosarcoma please! 
Passionate medical oncologist with experimental + public health agenda heading the Dpt. of General Medical Oncology + Lab. of Exp. Oncology at UZ/KU Leuven (BE)